[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT2121011E - Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe - Google Patents

Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe Download PDF

Info

Publication number
PT2121011E
PT2121011E PT78666328T PT07866632T PT2121011E PT 2121011 E PT2121011 E PT 2121011E PT 78666328 T PT78666328 T PT 78666328T PT 07866632 T PT07866632 T PT 07866632T PT 2121011 E PT2121011 E PT 2121011E
Authority
PT
Portugal
Prior art keywords
strains
influenza virus
including antigen
vaccines including
vaccines
Prior art date
Application number
PT78666328T
Other languages
English (en)
Inventor
Theodore F Tsai
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39492693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2121011(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2121011E publication Critical patent/PT2121011E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PT78666328T 2006-12-06 2007-12-05 Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe PT2121011E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87381506P 2006-12-06 2006-12-06

Publications (1)

Publication Number Publication Date
PT2121011E true PT2121011E (pt) 2014-07-31

Family

ID=39492693

Family Applications (1)

Application Number Title Priority Date Filing Date
PT78666328T PT2121011E (pt) 2006-12-06 2007-12-05 Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe

Country Status (13)

Country Link
US (3) US20110045022A1 (pt)
EP (3) EP2121011B1 (pt)
JP (1) JP2011506264A (pt)
CN (1) CN101553252A (pt)
AU (1) AU2007330494B2 (pt)
CA (2) CA2671629C (pt)
EA (1) EA200900784A1 (pt)
ES (1) ES2480491T3 (pt)
NZ (1) NZ577405A (pt)
PL (1) PL2121011T3 (pt)
PT (1) PT2121011E (pt)
SG (1) SG177141A1 (pt)
WO (1) WO2008068631A2 (pt)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
EP2010557B1 (en) 2006-03-31 2014-02-26 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
DK2066354T3 (da) 2006-09-29 2013-05-27 Ligocyte Pharmaceuticals Inc Norovirus vaccine formuleringer
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
CN101918028B (zh) 2007-09-18 2015-01-07 莱戈赛特医药股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
CA2737455A1 (en) * 2008-09-18 2010-03-25 Novartis Ag Vaccine adjuvant combinations
KR20110132373A (ko) 2009-02-10 2011-12-07 노파르티스 아게 유행병-연관 주에 대한 인플루엔자 백신 요법
US20120093860A1 (en) * 2009-02-10 2012-04-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
CN102307590A (zh) * 2009-02-10 2012-01-04 诺华有限公司 具有减少量的角鲨烯的流感疫苗
BRPI1011432A2 (pt) 2009-05-08 2019-09-24 Novartis Ag ensaios genericos para deteccao de virus influenza
EP2401384B1 (en) 2009-05-21 2012-10-03 Novartis AG Reverse genetics using non-endogenous pol i promoters
EP2437777B1 (en) * 2009-06-01 2014-09-17 Novartis AG COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES
CN102666860B (zh) 2009-07-31 2015-06-17 诺华股份有限公司 反向遗传系统
ES2454815T3 (es) 2009-10-20 2014-04-11 Novartis Ag Métodos mejorados de genética inversa para la recuperación de virus
EP2493912B1 (en) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
ES2461852T3 (es) 2009-12-03 2014-05-21 Novartis Ag Filtración hidrófila durante la fabricación de adyuvantes para vacunas
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2638895B1 (en) 2009-12-03 2024-03-20 Seqirus UK Limited Circulation of components during homogenization of emulsions
KR101579088B1 (ko) * 2009-12-03 2015-12-21 노파르티스 아게 미세 액화를 위한 상호작용 및 배압 챔버의 배치
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
JP6072677B2 (ja) 2010-05-06 2017-02-01 ノバルティス アーゲー 微生物の不活化のための有機ペルオキシド化合物
CA2800150C (en) 2010-05-21 2018-09-04 Novartis Ag Influenza virus reassortment method
WO2011150264A2 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Synthetic nanocarrier combination vaccines
PT2575873E (pt) 2010-06-01 2016-03-04 Novartis Ag Concentração de antigénios de vacinas com liofilização
WO2011151723A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
US8302323B2 (en) * 2010-06-21 2012-11-06 Confluent Surgical, Inc. Hemostatic patch
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9517205B2 (en) 2010-08-20 2016-12-13 Seqirus UK Limited Soluble needle arrays for delivery of influenza vaccines
WO2012032482A1 (en) 2010-09-07 2012-03-15 Novartis Ag Generic assays for detection of mammalian reovirus
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
US20120107354A1 (en) * 2010-10-30 2012-05-03 George Dacai Liu Viral vaccine and process for preparing the same
EP2678452B1 (en) * 2011-02-25 2016-02-24 Novartis AG Exogenous internal positive control for virus detection
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
BR112014000656A2 (pt) 2011-07-11 2017-02-14 Takeda Vaccines Inc formulações de vacina parenteral contra norovírus
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG11201401196WA (en) 2011-10-03 2014-05-29 Moderna Therapeutics Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2768528A1 (en) * 2011-10-20 2014-08-27 Novartis AG Adjuvanted influenza b virus vaccines for pediatric priming
SG10201604896TA (en) 2011-12-16 2016-08-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
CA2813723A1 (en) 2012-03-02 2013-09-02 Novartis Ag Influenza virus reassortment
WO2013151670A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
CN102650640A (zh) * 2012-04-24 2012-08-29 中国人民解放军第四军医大学 流感疫苗中的过敏原卵类粘蛋白或卵运铁蛋白定量检测
CA2875752A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
WO2014086732A2 (en) 2012-12-03 2014-06-12 Novartis Ag Influenza virus reassortment
CA2897752A1 (en) 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
MX2015011529A (es) 2013-03-13 2016-02-05 Novartis Ag Reordenamiento del virus de infuenza b.
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016521282A (ja) 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
CN105722976A (zh) 2013-06-06 2016-06-29 诺华股份有限公司 流感病毒重配
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Mdck、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
JP6881813B2 (ja) 2014-04-23 2021-06-02 モデルナティーエックス, インコーポレイテッド 核酸ワクチン
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
RU2587629C1 (ru) * 2014-12-29 2016-06-20 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Реассортантный штамм вируса гриппа rn9/13-human a(h6n9) для определения антител к нейраминидазе при гриппозной инфекции и вакцинации
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
RU2605317C1 (ru) * 2015-06-04 2016-12-20 Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) АДАПТИРОВАННЫЕ ПАНДЕМИЧЕСКИЕ ШТАММЫ ВИРУСА ГРИППА A/Tomsk/273/2010-MA1(H1N1pdm09), A/Tomsk/273/2010-MA2(H1N1pdm09) И A/Tomsk/273/2010-MA3(H1N1pdm09) ДЛЯ ОЦЕНКИ ДЕЙСТВИЯ ПРОТИВОВИРУСНЫХ ПРЕПАРАТОВ (ВАРИАНТЫ)
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2017062513A1 (en) 2015-10-05 2017-04-13 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
JP7336990B2 (ja) 2017-02-27 2023-09-01 フルゲン, インコーポレイテッド インフルエンザに対する免疫原性組成物
GB2562241B (en) * 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
US11278612B2 (en) * 2018-03-19 2022-03-22 Novavax, Inc. Multivalent influenza nanoparticle vaccines
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
MX2021010194A (es) 2019-02-25 2022-01-24 Seqirus Uk Ltd Vacunas contra la influenza multivalentes adyuvantadas.
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060082A (en) 1976-08-16 1977-11-29 Mpl, Inc. Dual-ingredient medication dispenser
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
GB8703696D0 (en) * 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ241926A (en) 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
KR970005274B1 (ko) * 1990-08-14 1997-04-15 아이시스 파마슈티칼스, 인코포레이티드 안티센스 올리고뉴클레오티드에 의한 a형 인플루엔자 바이러스, 안 아아보스트레인(ann arbor strain) h2n2의 억제
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
ES2131070T3 (es) 1991-03-01 1999-07-16 Minnesota Mining & Mfg 1h-imidazo(4,5-c)quinolin-4-aminas sustituidas en posicion 1 y sustituidas en posicion 2.
JPH0614756Y2 (ja) 1991-06-26 1994-04-20 株式会社アルテ 組み立て式の2室式容器兼用注射器
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
EP0708772B1 (en) 1993-07-15 2000-08-23 Minnesota Mining And Manufacturing Company IMIDAZO [4,5-c]PYRIDIN-4-AMINES
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5496284A (en) 1994-09-27 1996-03-05 Waldenburg; Ottfried Dual-chamber syringe & method
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
WO1998001174A1 (fr) 1996-07-05 1998-01-15 Debiotech S.A. Seringue a chambre double permettant le melange de deux produits avant leur injection
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
WO1999017820A1 (en) 1997-10-03 1999-04-15 Texas Pharmaceuticals, Inc. Improved dual chamber syringe apparatus
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
EP1075276B1 (en) 1998-05-07 2007-10-17 Corixa Corporation Adjuvant composition and methods for its use
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE19835749C1 (de) 1998-08-07 2000-02-03 Dieter Perthes Fertig-Spritze für nicht-stabile Arzneimittel
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
WO2000023105A2 (en) 1998-10-16 2000-04-27 Smithkline Beecham Biologicals S.A. Adjuvant systems and vaccines
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
MXPA01007895A (es) 1999-02-03 2003-07-21 Biosante Pharmaceuticals Inc Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos.
JP4800485B2 (ja) 1999-03-26 2011-10-26 バイカル インコーポレイテッド ポリヌクレオチドベースのワクチンに対する免疫応答を増強するためのアジュバント組成物および方法
WO2000060050A2 (en) 1999-04-06 2000-10-12 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
DE122007000070I1 (de) 1999-07-14 2008-01-31 Sinai School Medicine In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
AR025749A1 (es) 1999-09-24 2002-12-11 Smithkline Beecham Biolog Vacunas
CA2383413A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
ATE376825T1 (de) 1999-09-24 2007-11-15 Glaxosmithkline Biolog Sa Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
EP1700603A3 (en) 1999-09-25 2007-06-13 Coley Pharmaceutical GmbH Immunostimulatory nucleic acids
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
DE60142506D1 (de) 2000-03-03 2010-08-19 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
DE10012370A1 (de) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
KR100848719B1 (ko) 2000-04-28 2008-07-25 세인트 쥬드 칠드런즈 리써치 호스피탈 감염성 인플루엔자 바이러스 생성용 dna 트랜스펙션시스템
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
KR100877019B1 (ko) * 2000-06-23 2009-01-07 와이어쓰 홀딩스 코포레이션 야생형 및 키메릭 인플루엔자 바이러스성입자(브이엘피)의 조립
DE60140456D1 (de) 2000-09-01 2009-12-24 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
CA2421120C (en) 2000-09-11 2008-07-15 Chiron Corporation Quinolinone derivatives as tyrosine kinase inhibitors
ES2298269T3 (es) 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales.
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
EP2281573A3 (en) 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
AR032575A1 (es) 2001-02-23 2003-11-12 Smithkline Beecham Biolog Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna
WO2002072012A2 (en) 2001-03-09 2002-09-19 Id Biomedical Corporation Of Quebec A novel proteosome-liposaccharide vaccine adjuvant
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
NZ533628A (en) 2001-11-27 2006-07-28 Anadys Pharmaceuticals Inc 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
PT1499311E (pt) 2002-03-29 2010-03-10 Novartis Vaccines & Diagnostic Benzazois substituídos e sua utilização como inibidores da raf cinase
WO2003101949A2 (en) 2002-05-29 2003-12-11 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
US20060147477A1 (en) * 2002-06-11 2006-07-06 Glaxo Group Limited Immunogenic compositions
AU2003251518B2 (en) 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
KR20050038631A (ko) 2002-08-23 2005-04-27 카이론 코포레이션 글리코겐 신타제 키나제 3의 피롤 기제 억제제
AU2003300021A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
WO2004080403A2 (en) * 2003-03-07 2004-09-23 Merck & Co. Inc. Influenza virus vaccine
CA2517673C (en) * 2003-03-24 2013-08-13 Intercell Ag Improved vaccines for preventing viral infection
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
KR101153898B1 (ko) 2004-03-23 2012-06-18 니프로 가부시키가이샤 프리필드 시린지
CA2560969A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
EP2269644A3 (en) 2004-04-05 2012-10-17 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
RU2006145303A (ru) 2004-05-20 2008-06-27 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН (CA) Способ получения противогриппозной вакцины
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 免疫増強用の化合物
DE602005024827D1 (de) 2004-09-09 2010-12-30 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
CA2592120A1 (en) 2004-12-23 2006-07-06 Medimmune Vaccines, Inc. Non-tumorigenic mdck cell line for propagating viruses
NZ556061A (en) 2004-12-24 2009-06-26 Solvay Biologicals Bv Rescue of influenza virus
EP1851314A2 (en) * 2005-02-24 2007-11-07 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
KR20160064249A (ko) * 2005-03-23 2016-06-07 글락소스미스클라인 바이오로지칼즈 에스.에이. Cd4 t-세포 및/또는 개선된 b-메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
CA2646349A1 (en) * 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
US20100010199A1 (en) * 2006-09-11 2010-01-14 Novartis Ag Making influenza virus vaccines without using eggs
US20120093860A1 (en) * 2009-02-10 2012-04-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
AU2011225748A1 (en) * 2010-03-08 2012-09-13 Novartis Ag Methods of testing for intracellular pathogens

Also Published As

Publication number Publication date
EP2679240A1 (en) 2014-01-01
EP2532362A1 (en) 2012-12-12
WO2008068631A2 (en) 2008-06-12
EA200900784A1 (ru) 2009-12-30
JP2011506264A (ja) 2011-03-03
EP2121011A2 (en) 2009-11-25
CA2976230A1 (en) 2008-06-12
US20110045022A1 (en) 2011-02-24
EP2121011B1 (en) 2014-05-21
CA2671629C (en) 2017-08-15
AU2007330494B2 (en) 2014-03-13
CN101553252A (zh) 2009-10-07
AU2007330494A1 (en) 2008-06-12
US20190314483A1 (en) 2019-10-17
ES2480491T3 (es) 2014-07-28
US20140178429A1 (en) 2014-06-26
WO2008068631A8 (en) 2009-07-23
NZ577405A (en) 2012-08-31
CA2671629A1 (en) 2008-06-12
WO2008068631A3 (en) 2008-11-13
PL2121011T3 (pl) 2014-10-31
SG177141A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
PL2121011T3 (pl) Szczepionki zawierające antygeny czterech szczepów wirusa grypy
IL186611A0 (en) Vaccine against pandemic strains of influenza viruses
EP2217064A4 (en) NEW VACCINES AGAINST SEVERAL SUBTYPES OF THE INFLUENZAVIRUS
EP1984405A4 (en) INFLUENZA ANTIGENS, VACCINE COMPOSITIONS AND ASSOCIATED METHODS
ZA201004478B (en) Antibodies against influenza virus and methods of use thereof
IL203869A (en) Method of Preparing a Containing a Virus or Antigen Antigen, Various Aspects Related to This Method, Uses of a Method and Vaccination of a Split Virus Prepared by This Method
EP2091960A4 (en) PEPTIDE VACCINE AGAINST INFLUENZA VIRUS
IL210451A (en) Epitope for influenza virus vaccine
EP2552479A4 (en) INFLUENZA VIRUS VACCINES AND USES THEREOF
EP2118323A4 (en) DETECTION OF INFLUENZA VIRUS
EP1948227A4 (en) COMBINATORY ANTIGEN VACCINE AGAINST FLU
IL196024A0 (en) Influenza vaccine
EP2380976A4 (en) HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
EP1970707A4 (en) METHOD FOR DETECTION OF A VIRULENT STRAIN OF THE INFLUENZA VIRUS
SI2422810T1 (sl) Influenčno cepivo
ZA200809056B (en) Influenza virus vaccine
IL214385A (en) Inactive dengue virus vaccine with aluminum-free assists
GB0900772D0 (en) Live vaccine strains of francisella
EP1957101A4 (en) DSRNA AS INFLUENZA VIRUS IMPFSTOFF ADJUVANTIES OR IMMUNOSTIMULATORS
EP1998814A4 (en) NEW VACCINES AGAINST INFLUENZA M2
HUE051711T2 (hu) Influenzavakcina antigénjeinek koncentrálása liofilizálás nélkül
EP1871786A4 (en) PEPTIDE VACCINE AGAINST THE GRIPPEVIRUS
ZA201008125B (en) Inactivated live-attenuated bluetongue virus vaccine
EP2327714A4 (en) PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST FLUID VIRUS INFECTION
EP2195019A4 (en) METHOD FOR TRIGGERING AN IMMUNE RESPONSE AGAINST THE PANDEMIC INFLUENZA VIRUS